We finally assessed whether the reduction of DP cells by inhibition of IRAK1/4-NF-κB-PD-L1 pathway by either IRAK1/4 inhibitors or anti-PD-L1 antibody in combination with imatinib results in attenuating CML reconstitution activity by secondary transplantation. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.